Aliskiren/ACE Inhibitors; ARBs Interactions

This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking or discontinuing any drug or commencing any course of treatment.

Medical warning:

Serious. These medicines may interact and cause very harmful effects. Contact your healthcare professional (e.g. doctor or pharmacist) for more information.

How the interaction occurs:

How this interaction occurs is not known.

What might happen:

Taking these medicines together may increase your risk of stroke, kidney problems, excessively low blood pressure, or low potassium levels in your blood.

What you should do about this interaction:

Make sure your healthcare professionals (e.g. doctor or pharmacist) know that you are taking these medicines together and if you have diabetes and/or kidney problems. Your doctor may want to check your blood pressure, perform some blood tests, or change your medicine. Let your doctor know if you feel faint, dizzy, confused, or have any symptoms of a stroke.Your healthcare professionals may already be aware of this interaction and may be monitoring you for it. Do not start, stop, or change the dosage of any medicine before checking with them first.

  • 1.Anonymous. Novartis announces termination of ALTITUDE study with Rasilez/Tekturna in high-risk patients with diabetes and renal impairment. available at: http://www.novartis.com/downloads/newsroom/rasilez-tekturna-information-ce nter/20111220-rasilez-tekturna.pdf December, 20, 2011.
  • 2.USFood and Drug Administration. FDA Drug Safety Communication: New Warning and Contraindication for blood pressure medicines containing aliskiren (Tekturna). available at: http://www.fda.gov/Drugs/DrugSafety/ucm300889.htm April 20, 2012.
  • 3.Health Canada. Rasilez (aliskiren): Health Canada reviewing safety of blood-pressure drug. available at: http://www.healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2011/1357 2a-eng.php December 22, 2011.
  • 4.Leclerc JM. Dear Canadian Healthcare Professional letter: Subject: Potential risks of cardiovascular and renal adverse events in patients with type 2 diabetes treated with aliskiren (RASILEZ) or aliskiren/hydrochlorothiazide (RASILEZ HCT). Novartis January 18, 2012.
  • 5.Zestril (lisinopril) US prescribing information. AstraZeneca Pharmaceuticals LP July 21, 2017.